The Millionaires Club A forum where gentlepersons may discuss finance and related matters
wit is appreciated - vulgarity is not

Introduction

View Introduction

Archives

View Archives

Search Archives

Info

Adding Images

Adding Links

Links

 aaa Brown attacked by M|EP

 aaa The Great GW Circus

 ADVFN

 AIM

 Barclays Stockbrokers

 BBC

 Bloomberg

 Bullion Desk

 CMC

 CNN

 Companies House

 CSY Computer Systems

 Daily Bayonet

 Dailyfx

 Digital Look

 Fark

 French Property

 FT.com

 Google

 Growthcompany Info

 IG Index

 Interactive Investor

 Live Oil Price

 London Stock Exchange

 Money AM

 Motley Fool

 MSN Money

 Nasdaq

 New York Stock Exchange

 News of the World

 Shares mag

 Sky News

 Stockchallenge

 The Daily Mail

 The Daily Telegraph

 The Dailymash

 The Financial Times

 The Guardian

 The Indepenent

 The New York Times

 The Sun

 The Times Online

 The Wall Street Journal

 Wikipedia

 Yahoo

 You tube


Current Message Return to posts
From: Hamsterwheel
TRX will be worth $1bn, which is nice.

Tissue Regenix's takeover value may eventually top US$1bn suggests broker
By Philip Whiterow December 05 2013, 10:56am

Medtech group Tissue Regenix (LON:TRX) could be worth more than US$1bn if all of its product areas take off, a punchy note from US broker Jefferies has suggested.

The launch soon of its first product, a wound care treatment, could see the shares double in value as the story de-risks and first sales are generated, the house suggested.

“Eventually, if the products deliver on their promising early results, we would expect interest from the global medtech companies, and if each product area works, we see the potential for Tissue to be a US$1bn company.”

Tissue Regenix’s technology can be used to replace human body parts and addresses markets that today are valued at more than US$10bn, it said.
Its proprietary method of washing human and animal tissue has shown very promising results in small data sets, and Jefferies suggests there is significant upside from a successful launch of its skin replacement for wounds.
"The trial results and initial sales over the next 12-24 months could see Tissue Regenix become a takeover target," it said. The large medical device companies are grappling with how to move beyond metal and plastic implants, and the company can deliver a neat affordable solution.

As well as wound care, Tissue Regenix is developing products for meniscus and ligament repair and heart valve replacements, among others.

In heart valves, for example, Tissue has eight years of clinical data from Brazil and it has proved so superior to alternatives one tissue bank is now only using its process.

Companies with products addressing similar needs have fetched valuations of US$500-700mln. Tissue Regenix has several product areas and so will get several shots at goal, Jefferies adds.

Based on historical takeover valuations, all of these areas combined could be worth "north of US$1.5bn or about 10 times the current share price in a break-up and take-out scenario".

 Messages  Author  Time  Date 
TRX will be worth $1bn, which is nice....[more]
 Hamsterwheel  08:25:35  25/02/2014 
>> yes well done RR great shout
 Alfie Noakes  10:10:04 
>> *$(%^)$&U$ *"*$**%()$+_£ (£("£U$+$ !!!!!
 Hamsterwheel  10:21:37 
>> :)
 Alfie Noakes  10:25:45 
>> More TRXplosive...[more]
 Hamsterwheel  14:28:25 


© 2000 sell on the internet (soti) ltd | feedback
www.the-millionaires-club.co.uk ... FTIR Investments of Geneva Place, Road Town, British Virgin Islands